The Ministry of Food and Drug Safety (MInister: Yu-kyoung Oh) approved two dosage forms (50mg, 150mg) of MSD Korea’s new breast cancer drug Tukysa (tucatinib) on the 14th.

The drug is used in combination with trastuzumab and capecitabine, for patients with locally advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Tucatinib is a tyrosine kinase inhibitor (TKI) that is a selective and potent inhibitor of the HER2 receptor overexpressed on cancer cells. It blocks the intracellular signaling pathway of HER2 to inhibit the survival, proliferation, and metastasis of tumor cells and induce cellular apoptos